Red Light uses Researgency.ai to develop PEX010

Executive Summary

• Red Light Holland Corp. has engaged Kala Bio Inc.'s Researgency.ai platform to support the clinical development strategy for PEX010, a patented botanical psilocybin drug candidate originating from Filament Health Corp.
• This engagement follows Red Light's recent announcement of a definitive arrangement agreement to acquire Filament Health, including its lead drug candidate PEX010 and a portfolio of 76 issued patents.
• PEX010 is currently supplied to over 70 clinical research sites globally, has received Health Canada and FDA authorization for clinical trials, and has demonstrated positive Phase 2 data for alcohol use disorder.

Key Details

• AI Platform Engagement: Red Light Holland engaged Kala Bio’s Researgency.ai (an agentic AI platform developed by Younet.ai) to assist with clinical planning, protocol optimization, and scenario modeling for PEX010.
• Acquisition Context: The AI engagement is part of Red Light’s strategy to integrate Filament’s assets following a definitive arrangement agreement to acquire Filament’s business, including 76 issued patents across 15 patent families.
• PEX010 Clinical Status:
  • Currently supplied to more than 70 clinical research sites worldwide.
  • Studied across multiple indications: alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder.
  • Investigated at leading institutions including Johns Hopkins University and Dana-Farber Cancer Institute.
  • Received Health Canada and U.S. FDA authorization for clinical trials.
  • Demonstrated positive Phase 2 clinical data in alcohol use disorder.
• Advisory Services: Red Light engaged Solidaire Investments Inc. (a merchant bank based in Calgary) for capital market advisory and investor relations consulting.
  • Term: One month, effective immediately.
  • Fee: $20,000.
  • Ownership: Solidaire is principally owned by Mohamed Elsaghir, a shareholder of Red Light Holland.
• Strategic Rationale: The company aims to accelerate research planning, enhance scenario simulation, and optimize protocols using autonomous AI-driven research capabilities to build a "best-in-class" psychedelic drug development operation.

Notable Quotes

• Todd Shapiro, CEO of Red Light Holland: "As we move to integrate Filament's exceptional clinical assets and intellectual property, engaging Kala Bio's Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation... By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs and make smarter, faster decisions across PEX010's extensive clinical program."
• Ben Lightburn, CEO of Filament Health: "With PEX010 already supporting a growing body of global clinical research, the application of advanced analytical tools such as Kala Bio's Researgency.ai platform has the potential to further strengthen how clinical development strategies are evaluated as the program continues to evolve."
• Avi Minkowitz, CEO of Kala Bio: "Red Light's decision to deploy Researgency.ai in support of PEX010 underscores exactly the kind of high-value, data-intensive challenge our platform was built to address... We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world."